Current treatment status-Undergoing active treatment-Complete remission Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Complete remission Posts on Medivizor

Avoiding consolidation radiotherapy in advanced Hodgkin lymphoma with large nodes after ABVD chemotherapy

Avoiding consolidation radiotherapy in advanced Hodgkin lymphoma with large nodes after ABVD chemotherapy

Posted by on Sep 26, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated the impact of consolidation radiotherapy (cRT) on patients with advanced Hodgkin lymphoma (HL) who had large nodal mass (LNM) and currently in complete metabolic response (CMR) after receiving ABVD chemotherapy. The authors found that cRT could be safely avoided in such patients. Some background CMR defines...

Read More

Treating acute myeloid leukemia with FLT3-ITD mutation by sorafenib maintenance after HSCT

Treating acute myeloid leukemia with FLT3-ITD mutation by sorafenib maintenance after HSCT

Posted by on Aug 23, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated outcomes of sorafenib (Nexavar) maintenance therapy after allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with acute myeloid leukemia (AML) carrying FLT3-ITD mutation. The authors found that sorafenib maintenance therapy decreased the risks of relapse and mortality after HSCT in such...

Read More

Decitabine, cytarabine and umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia

Posted by on Sep 17, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the combination of low-dose decitabine, medium-dose cytarabine and umbilical cord blood infusion as a consolidation therapy for elderly patients with acute myeloid leukemia.   This study concluded that this treatment combination was effective in these patients.   Some...

Read More

Stem cell transplantation and lenalidomide improves survival of patients with multiple myeloma

Posted by on Dec 5, 2018 in Multiple Myeloma | 0 comments

In a nutshell This article investigated the safety and effectiveness of high-dose therapy with autologous stem cell transplantation (HDT-ASCT) and maintenance treatment (treatment meant to keep cancer from coming back) with lenalidomide (Revlimid) for patients with multiple myeloma. The authors concluded that this therapy is safe...

Read More

Evaluating nilotinib as a consolidation therapy for patients with chronic myeloid leukemia

Posted by on Sep 8, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the effectiveness of nilotinib as a consolidation therapy for patients with chronic myeloid leukemia who had achieved a major response with imatinib. This study concluded that nilotinib led to safer, deeper responses in these patients. Some background Imatinib (Gleevec) is a tyrosine kinase inhibition (TKI)...

Read More

Overall survival and relapse rate in adults with AML who have received a stem cell transplant from a donor

Posted by on Aug 1, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to identify the outcomes and prognostic factors following a stem cell transplant from a donor in adults with acute myeloid leukemia in their second complete remission (no sign of disease). The authors determined that this type of transplant was effective in these patients. Some background In adult patients with acute...

Read More

Is mismatched donor stem cell transplantation an effective treatment in high-risk relapse of ALL?

Posted by on Jun 25, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the effectiveness of mismatched donor stem cell transplantation (SCT) for treating children with high-risk relapse of acute lymphoblastic leukemia (ALL). Researchers found that mismatched donor SCT was useful but not as effective as matched donor SCT in children with high-risk ALL. Some background Acute lymphoblastic...

Read More

What are the long-term outcomes after plerixafor and G-CSF before stem cell transplantation?

Posted by on Mar 8, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term outcomes of patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM) who received plerixafor (Mozobil) or placebo combined with G-CSF (granulocyte colony stimulating factor) before a stem cell transplant (SCT). This study concluded that adding plerixafor to G-CSF did not negatively...

Read More